(Reuters) – GSK said on Friday that its respiratory syncytial virus (RSV) vaccine has received approval in Japan for expanded use in adults aged between 50 and 59, who are at increased risk of severe RSV disease.
GSK’s RSV vaccine Arexvy has been approved in Japan for adults aged 60 and over since September last year for the prevention of the disease caused by RSV, a common contagious virus that affects the lungs and breathing passages.
The approval in Japan will be a shot in the arm for GSK, which has slashed its 2024 vaccine sales forecast twice this year.
The nod for expanded use of Arexvy in Japan comes after GSK last month flagged that its vaccine sales would fall this year, partly due to declining Shingrix sales in the U.S. and China and a weaker-than-expected third quarter for RSV sales in the U.S.
GSK’s RSV vaccine has been approved for adults aged between 50 and 59 at increased risk in 35 countries, the company said in a statement.
(Reporting by Aby Jose Koilparambil in Bengaluru; Editing by Abinaya Vijayaraghavan)
Comments